|
KaloBios Receives Notice of Allowance for Key Composition of Matter Patent Covering KBOO4
Dec 5, 2013
|
14.5 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Dec. 5, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a composition of matter patent covering certain antibodies targeting EphA3, including KaloBios' experimental anti-cancer monoclonal antibody (mAb), KB...
|
|
KaloBios Reports Third Quarter 2013 Financial Results
Nov 12, 2013
|
23.2 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) a biopharmaceutical company with a portfolio of patient-targeted, first-in-class, monoclonal antibodies (mAbs) to treat severe respiratory diseases and cancer, announced today its corporate highlights and financial results for the third quarter ...
|
|
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Nov 7, 2013
|
15.1 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Nov. 7, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that data from its ongoing Phase 1 trial of KB004, an anti-EphA3 monoclonal antibody (mAb), will be presented at a poster session at the 55th American Society of Hematology (ASH) Annual Meeting and Exhibition. The Phase 1 trial of...
|
|
U.S. FDA Grants Orphan Drug Designation for KaloBios' KB001-A in Treatment of Cystic Fibrosis Patients
Oct 30, 2013
|
14.9 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the U.S. Food & Drug Administration (FDA) has granted the company orphan drug designation for KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, for the treatment of cystic fibrosis (CF) patients with Pseudomonas aeru...
|
|
KaloBios Elects Laurie Smaldone Alsup, M.D. to Board
Oct 23, 2013
|
14.1 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the election of Laurie Smaldone Alsup, M.D. to KaloBios' Board of Directors.
(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)
"Dr. Smaldone Alsup brings to the Board extensive experience in leading te...
|
|
KaloBios Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Oct 1, 2013
|
9.1 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Oct. 1, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (KaloBios) (NASDAQ:KBIO) today announced the completion of its public offering of 8,625,000 shares of common stock at $4.00 per share, which included 1,125,000 shares issued upon the exercise in full of the underwriters' option to purchase additional shares. Th...
|
|
KaloBios to Present at Leerink Swann Rare Disease Roundtable
Sep 30, 2013
|
9.4 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company will present at the Leerink Swann Rare Disease Roundtable on October 2 at the Le Parker Meridien in New York City. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBi...
|
|
KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
Sep 26, 2013
|
12.2 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (KaloBios) (NASDAQ: KBIO) today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $4.00 per share. The net offering proceeds to KaloBios are expected to be approximately $27,855,000 mi...
|
|
KaloBios to Present at BioCentury's NewsMakers in the Biotech Industry Conference
Sep 23, 2013
|
9.4 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will present at the BioCentury NewsMakers in the Biotech Industry Conference on September 27 at the Millennium Broadway Hotel & Conference Center in New York City. KaloBios President and Chief Executive Officer,...
|
|
KaloBios Pharmaceuticals, Inc. Proposes Public Offering of Common Stock
Sep 23, 2013
|
11.8 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (KaloBios) (NASDAQ: KBIO) today announced that it is offering to sell shares of its common stock in an underwritten public offering. KaloBios also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock offered in t...
|
|
Herb C. Cross to Join KaloBios as Chief Financial Officer
Sep 19, 2013
|
14.7 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that Herb C. Cross will join the company as of September 23, 2013, and transition into the Chief Financial Officer role in coordination with Jeffrey H. Cooper, the company's current CFO. The company expects this transition will...
|
|
KaloBios' KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
Sep 18, 2013
|
15.5 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced the publication of Phase 1 study results for KB001, a first generation, anti-Pseudomonas aeruginosa (Pa) type III secretion system (TTSS) antibody, for use in patients with cystic fibrosis (CF). Data from this initial single dose...
|
|
KaloBios to Present at Stifel Healthcare Conference 2013
Sep 5, 2013
|
9.4 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company will present at the Stifel Healthcare Conference 2013 on September 12 at the Four Seasons Hotel in Boston. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and th...
|
|
KaloBios Reports Second Quarter 2013 Financial Results
Aug 19, 2013
|
22.9 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) a biopharmaceutical company with a portfolio of patient-targeted, first-in-class, monoclonal antibodies (mAbs) to treat serious medical conditions with a primary clinical focus on severe respiratory diseases and cancer, announced today its corpo...
|
|
KaloBios Appoints V. Bryan Lawlis, Jr., Ph.D. to Board of Directors
Aug 7, 2013
|
14.2 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Aug. 7, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of V. Bryan Lawlis, Jr., Ph.D. to the KaloBios Board of Directors. Dr. Lawlis is President and Chief Executive Officer of Itero Biopharmaceuticals, LLC and also serves as a Director of Biomarin Pharmaceutical, Gero...
|
|
KaloBios Announces Retirement Of Chief Financial Officer
Aug 5, 2013
|
13.6 KB |
|
|
SOUTH SAN FRANCISCO, Calif., Aug. 5, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the retirement of Jeffrey H. Cooper, the company's Chief Financial Officer, effective as of December 31, 2013. Mr. Cooper has decided to retire in order to dedicate more time to family and personal interests. Mr. Cooper has commi...
|
|
KaloBios to Present at 2013 JMP Securities Healthcare Conference
Jul 2, 2013
|
9.3 KB |
|
|
SOUTH SAN FRANCISCO, Calif., July 2, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will present at the 2013 JMP Securities Healthcare Conference on July 10 in New York City. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company'...
|
|
KaloBios Provides Update on Pipeline of Clinical Programs
Jun 27, 2013
|
14.1 KB |
|
|
SOUTH SAN FRANCISCO, Calif., June 27, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on the status of its ongoing clinical programs for KB003, KB001-A and KB004, its pipeline of proprietary monoclonal antibodies in development for severe respiratory diseases and cancer.
(Logo: http://photos.prnew...
|
|
KaloBios Appoints Donald R. Joseph as Chief Legal Officer
Jun 17, 2013
|
14.2 KB |
|
|
SAN FRANCISCO, June 17, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Donald R. Joseph as Chief Legal Officer. Mr. Joseph brings to KaloBios almost 20 years of biopharmaceutical industry experience and has worked in both public and private companies, as well as major global health non-profit ...
|
|
KaloBios Reports First Quarter 2013 Financial Results
May 14, 2013
|
21.3 KB |
|
|
SOUTH SAN FRANCISCO, Calif., May 14, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) a biopharmaceutical company with a portfolio of patient-targeted, first-in-class, antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer, announced today its financial results for the first ...
|
|